$SPRO News

Spero Therapeutics Q1 EPS $(0.13) Beats $(0.18) Estimate, Sales $258.000K Down From $5.874M YoY

Uncovering 3 Penny Stocks With Market Caps Under $700M

Spero Therapeutics Inc (NASDAQ:SPRO) Reports Q4 Earnings Beat and Positive Regulatory Step

Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update

Spero Therapeutics Q4 EPS $0.53 Beats $(0.40) Estimate, Sales $41.297M Up From $15.044M YoY

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

Spero Therapeutics: Tebipenem's FDA Path Supports A Speculative Buy

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Is Spero Therapeutics (NASDAQ:SPRO) In A Good Position To Deliver On Growth Plans?

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Spero Therapeutics Q3 EPS $(0.13) Beats $(0.39) Estimate, Sales $5.442M Down From $13.469M YoY

Insights Ahead: Spero Therapeutics's Quarterly Earnings

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Spero Therapeutics, Inc. (SPRO) Presents at IDWeek 2025 - Slideshow

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

Best Momentum Stock to Buy for October 10th

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

Spero Therapeutics shares are trading lower following the release of its Q2 financial results.